Embryonal carcinoma (EC) is a malignant, non-seminomatous germ cell tumour composed of primitive epithelial-appearing cells growing in solid, glandular and pseudopapillary patterns with high-grade nuclei, brisk mitotic activity and geographic necrosis. It is the least differentiated and most pluripotent of the germ cell tumour histologies: EC cells retain an embryonic-stem-cell-like transcriptional programme (OCT3/4/POU5F1, SOX2, NANOG, LIN28) and can differentiate into the other germ cell tumour lineages, which is why EC is the most common component of post-pubertal mixed germ cell tumours and is only rarely encountered in pure form. Like other GCNIS-derived (type II) germ cell tumours it carries isochromosome 12p or another form of 12p gain as its near-universal cytogenetic lesion. EC arises most often in the testis, less commonly in the ovary, and at extragonadal midline sites including the central nervous system and mediastinum. Its immunophenotype (OCT3/4-positive, SOX2-positive, CD30-positive, SOX17-negative) is what separates it from seminoma/germinoma. Clinically EC is aggressive - a high proportion of EC in an orchiectomy specimen predicts occult metastatic disease - yet it is also exceptionally curable, because retained wild-type TP53, limited DNA repair capacity and an intact apoptotic apparatus make it profoundly sensitive to cisplatin-based combination chemotherapy.
Ask a research question about Embryonal Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Embryonal Carcinoma:
name: Embryonal Carcinoma
creation_date: "2026-08-18T00:00:00Z"
description: >-
Embryonal carcinoma (EC) is a malignant, non-seminomatous germ cell tumour composed of
primitive epithelial-appearing cells growing in solid, glandular and pseudopapillary
patterns with high-grade nuclei, brisk mitotic activity and geographic necrosis. It is
the least differentiated and most pluripotent of the germ cell tumour histologies: EC
cells retain an embryonic-stem-cell-like transcriptional programme (OCT3/4/POU5F1,
SOX2, NANOG, LIN28) and can differentiate into the other germ cell tumour lineages,
which is why EC is the most common component of post-pubertal mixed germ cell tumours
and is only rarely encountered in pure form. Like other GCNIS-derived (type II) germ
cell tumours it carries isochromosome 12p or another form of 12p gain as its
near-universal cytogenetic lesion. EC arises most often in the testis, less commonly in
the ovary, and at extragonadal midline sites including the central nervous system and
mediastinum. Its immunophenotype (OCT3/4-positive, SOX2-positive, CD30-positive,
SOX17-negative) is what separates it from seminoma/germinoma. Clinically EC is
aggressive - a high proportion of EC in an orchiectomy specimen predicts occult
metastatic disease - yet it is also exceptionally curable, because retained wild-type
TP53, limited DNA repair capacity and an intact apoptotic apparatus make it profoundly
sensitive to cisplatin-based combination chemotherapy.
categories:
- Germ Cell Neoplasm
- Solid Tumor
parents:
- non-seminomatous germ cell tumor
- germ cell tumor
disease_term:
preferred_term: embryonal carcinoma
term:
id: MONDO:0005440
label: embryonal carcinoma
classifications:
icdo_morphology:
classification_value: Embryonal Neoplasm
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
has_subtypes:
- name: Testicular EC
display_name: Testicular embryonal carcinoma
subtype_term:
preferred_term: testicular embryonal carcinoma
term:
id: MONDO:0006446
label: testicular embryonal carcinoma
description: >-
Embryonal carcinoma arising in the testis, by far the commonest site. It is a
GCNIS-derived (type II) germ cell tumour and is usually one component of a mixed
non-seminomatous germ cell tumour rather than a pure tumour. Diagnosis rests on
high-grade embryonal-carcinoma-like nuclear morphology supported by an
OCT3/4-positive, SOX2-positive, CD30-positive, SOX17-negative immunophenotype.
Management follows non-seminoma pathways: radical inguinal orchiectomy, then
surveillance, retroperitoneal lymph node dissection or cisplatin-based chemotherapy
according to stage and risk.
evidence:
- reference: PMID:38922953
reference_title: "Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Type II GCT include seminoma, embryonal carcinoma, choriocarcinoma,
postpubertal-type teratoma and postpubertal-type YST.
explanation: >-
Places testicular embryonal carcinoma within the GCNIS-derived type II group of
testicular germ cell tumours.
- name: Ovarian EC
display_name: Ovarian embryonal carcinoma
subtype_term:
preferred_term: ovarian embryonal carcinoma
term:
id: MONDO:0003581
label: ovarian embryonal carcinoma
description: >-
Embryonal carcinoma arising in the ovary. It is one of the rarest malignant ovarian
germ cell tumours, occurring in girls and young women, and is more often a component
of a malignant mixed germ cell tumour than a pure tumour. It typically presents as a
large unilateral solid adnexal mass with beta-hCG and/or AFP elevation.
evidence:
- reference: PMID:33142349
reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
From the International Ovarian Tumor Analysis (IOTA) database, we identified
patients with a histological diagnosis of ovarian embryonal carcinoma,
non-gestational choriocarcinoma or malignant mixed germ cell tumor
explanation: >-
Establishes ovarian embryonal carcinoma as a distinct, separately diagnosed rare
malignant ovarian germ cell tumour entity.
- name: CNS EC
display_name: Embryonal carcinoma of the central nervous system
subtype_term:
preferred_term: embryonal carcinoma of the central nervous system
term:
id: MONDO:0018843
label: embryonal carcinoma of the central nervous system
description: >-
Intracranial embryonal carcinoma, one of the non-germinomatous germ cell tumour
(NGGCT) histologies. Intracranial germ cell tumours arise predominantly in the pineal
and suprasellar regions of children and adolescents and present with raised
intracranial pressure, visual disturbance and endocrine failure rather than a mass
lesion at a gonadal site. Unlike germinoma, NGGCT requires intensive chemotherapy,
resection of residual tumour and high-dose radiotherapy, and its prognosis is more
guarded.
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
NGGCTs include embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratomas
and often secrete tumor markers like alpha-fetoprotein (AFP) and beta-hCG, which
guide diagnosis and treatment without biopsy.
explanation: >-
Places embryonal carcinoma among the intracranial non-germinomatous germ cell
tumour histologies and describes their marker-driven diagnosis.
- name: Non-CNS-localized EC
display_name: Non-central nervous system-localized embryonal carcinoma
subtype_term:
preferred_term: non-central nervous system-localized embryonal carcinoma
term:
id: MONDO:0017328
label: non-central nervous system-localized embryonal carcinoma
description: >-
Embryonal carcinoma at any site other than the central nervous system. This
Orphanet-derived concept is defined purely by exclusion of the CNS, so it does not
partition cleanly against its sibling subtypes here: it properly subsumes both
Testicular EC (MONDO:0006446) and Ovarian EC (MONDO:0003581), which are the great
majority of non-CNS disease. What it uniquely adds beyond those two gonadal subtypes
are the extragonadal midline presentations outside the CNS - most importantly the
anterior mediastinum, and less often the retroperitoneum and sacrococcygeal region -
which are thought to arise from primordial germ cells misrouted during embryonic
migration. Mediastinal disease in particular carries a higher rate of TP53 mutation
and a worse prognosis than gonadal disease.
evidence:
- reference: PMID:26191277
reference_title: "Extragonadal malignant germ cell tumors: a clinicopathological and immunohistochemical analysis of 48 cases at a single Chinese institution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primary extragonadal malignant germ cell tumors (EMGCTs) are rare and characterized
by the location in the midline of the body, including mediastinum, CNS,
retroperitoneum and coccyx.
explanation: >-
Documents the extragonadal midline sites, of which the non-CNS ones define this
subtype.
prevalence:
- population: Pure embryonal carcinoma among testicular germ cell tumours
measure_type: POINT_PREVALENCE
prevalence_class: RARE
notes: >-
Pure embryonal carcinoma is uncommon; EC is encountered far more often as a component
of a post-pubertal mixed germ cell tumour, where it is the most common
non-seminomatous element. No numeric rate is given here because the published figures
are component-frequency proportions within surgical series rather than population
rates.
- population: Children and adolescents with intracranial germ cell tumours
measure_type: POINT_PREVALENCE
prevalence_class: RARE
notes: >-
Intracranial embryonal carcinoma is a histology within the intracranial NGGCT group;
intracranial germ cell tumours as a whole are rare and account for up to 20% of
paediatric germ cell tumours, with a higher incidence in East Asian populations.
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Intracranial germ cell tumors (iGCTs) are rare neoplasms that predominantly affect
children and adolescents, accounting for up to 20% of pediatric germ cell tumors
and showing higher incidence in East Asian populations.
explanation: >-
Supports the rarity of the intracranial germ cell tumour group that contains
intracranial embryonal carcinoma.
pathophysiology:
- name: GCNIS-Derived Germ Cell Transformation
description: >-
Post-pubertal embryonal carcinoma is a type II germ cell tumour: it develops from
germ cell neoplasia in situ (GCNIS), a non-invasive intratubular lesion of arrested
fetal germ cells that retains embryonic pluripotency factors. Progression from GCNIS
to an invasive tumour is the initiating event, and the same precursor gives rise to
seminoma, embryonal carcinoma, choriocarcinoma, yolk sac tumour and post-pubertal
teratoma - which is why these histologies co-occur in mixed tumours.
biological_scale: CELLULAR
cell_types:
- preferred_term: primordial germ cell
term:
id: CL:0000670
label: primordial germ cell
biological_processes:
- preferred_term: cell differentiation
modifier: ABNORMAL
term:
id: GO:0030154
label: cell differentiation
locations:
- preferred_term: testis
term:
id: UBERON:0000473
label: testis
evidence:
- reference: PMID:38922953
reference_title: "Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Type II GCT develop from a non-invasive germ cell neoplasia in situ (GCNIS) and
show an isochromosome 12p (i12p) or gain of 12p material as a common and
characteristic molecular alteration.
explanation: >-
Establishes GCNIS as the precursor lesion for the type II germ cell tumours that
include embryonal carcinoma, and links progression to 12p gain.
downstream:
- target: Isochromosome 12p Formation and 12p Gain
description: >-
Acquisition of i(12p) or other 12p gain accompanies progression from intratubular
GCNIS to invasive tumour.
- name: Isochromosome 12p Formation and 12p Gain
description: >-
Gain of the short arm of chromosome 12, most often as an isochromosome, is the
near-universal cytogenetic lesion of GCNIS-derived germ cell tumours including
embryonal carcinoma. It is thought to be acquired during progression from GCNIS to
invasive disease and is diagnostically useful for confirming germ cell origin in
primary and metastatic lesions. 12p carries NANOG, KRAS, CCND2 and LDHB, so the gain
simultaneously raises the dosage of a pluripotency factor, a mitogenic GTPase, a G1
cyclin and a glycolytic enzyme. Embryonal carcinoma otherwise has a strikingly quiet
point-mutation landscape; its genomic instability is chromosomal (aneuploidy) rather
than a mutator phenotype.
biological_scale: MOLECULAR
biological_processes:
- preferred_term: chromosome organization
modifier: ABNORMAL
term:
id: GO:0051276
label: chromosome organization
genes:
- preferred_term: KRAS
term:
id: hgnc:6407
label: KRAS
- preferred_term: CCND2
term:
id: hgnc:1583
label: CCND2
- preferred_term: NANOG
term:
id: hgnc:20857
label: NANOG
- preferred_term: LDHB
term:
id: hgnc:6541
label: LDHB
evidence:
- reference: PMID:41384700
reference_title: "Molecular pathology of testicular germ cell tumours: an update for practicing pathologists."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is thought that the isochromosome 12p develops during the progression of a GCNIS
to an invasive TGCT.
explanation: >-
Times the acquisition of i(12p) to the GCNIS-to-invasive-tumour transition modelled
by the upstream node.
- reference: PMID:36030288
reference_title: "Molecular correlates of male germ cell tumors with overgrowth of components resembling somatic malignancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Gains in the short arm of chromosome 12 were seen in 91% of cases, likely
reflecting the presence of isochromosome 12p.
explanation: >-
Quantifies the near-universal 12p gain in a molecularly profiled male germ cell
tumour series.
- reference: PMID:32205480
reference_title: "Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Detection of gain of the short arm of chromosome 12 is diagnostic to differentiate
between non-GCNIS versus GCNIS related GCTs and supportive to the germ cell origin
of both primary and metastatic tumors.
explanation: >-
Supports 12p gain as the diagnostic marker of GCNIS-derived germ cell tumours,
including embryonal carcinoma.
downstream:
- target: Retained Embryonic Pluripotency Program
description: >-
Extra copies of 12p-resident NANOG contribute to maintaining the embryonic
pluripotency transcriptional network.
- target: Unrestrained Primitive Epithelial Proliferation
description: >-
Increased dosage of the 12p-resident mitogenic genes KRAS and CCND2 supports
proliferation.
- name: Epigenetic Regulation of the Pluripotency Driver Genes
description: >-
Which pluripotency driver panel a GCNIS-derived tumour expresses is set epigenetically
rather than by mutation of the driver genes themselves. Cytosine methylation of DNA
and methylation/acetylation of histone 3 lysines regulate expression of these drivers
between the TGCT subtypes, and this is the layer at which embryonal carcinoma's
OCT4/SOX2/LIN28/NANOG panel diverges from the OCT4/SOX17/KLF4/MYC panel of seminoma.
It is therefore the upstream determinant of the SOX2-positive, SOX17-negative
immunophenotype the entry uses diagnostically, and of the switch in panel that
accompanies the seminoma-to-EC distinction.
biological_scale: MOLECULAR
biological_processes:
- preferred_term: epigenetic regulation of gene expression
modifier: ABNORMAL
term:
id: GO:0040029
label: epigenetic regulation of gene expression
evidence:
- reference: PMID:36835562
reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Epigenetic mechanisms, such as methylations of cytosines on the DNA string and
methylations and acetylations of histone 3 lysines, regulate expression of these
driver genes between the TGCT subtypes.
explanation: >-
States directly that epigenetic mechanisms regulate the pluripotency driver genes
across testicular germ cell tumour subtypes, which is the claim of this node.
- reference: PMID:36835562
reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a seminoma subtype expresses an induced pluripotent stem cell (iPSC) panel with four
upregulated genes, OCT4/POU5F1, SOX17, KLF4, and MYC, and embryonal carcinoma (EC)
has four upregulated genes, OCT4/POU5F1, SOX2, LIN28, and NANOG
explanation: >-
Documents the specific EC-versus-seminoma driver panel difference that the
epigenetic layer modelled here regulates.
downstream:
- target: Retained Embryonic Pluripotency Program
description: >-
Epigenetic derepression of the OCT4/SOX2/LIN28/NANOG panel is what establishes and
maintains the embryonal carcinoma pluripotency state.
- name: Retained Embryonic Pluripotency Program
description: >-
The defining molecular feature of embryonal carcinoma is retention of an
embryonic-stem-cell-like transcriptional programme. EC cells co-express OCT3/4
(POU5F1), SOX2, NANOG and LIN28; this quartet is sufficient to reprogramme somatic
cells to induced pluripotency, and EC itself behaves as a malignant pluripotent stem
cell. The SOX2-positive, SOX17-negative pattern is what distinguishes EC from
seminoma/germinoma, which shares OCT3/4 but expresses SOX17 instead.
biological_scale: MOLECULAR
cell_types:
- preferred_term: pluripotent stem cell
term:
id: CL:0002248
label: pluripotent stem cell
biological_processes:
- preferred_term: stem cell population maintenance
modifier: INCREASED
term:
id: GO:0019827
label: stem cell population maintenance
gene_products:
- preferred_term: OCT3/4
term:
id: NCIT:C61142
label: POU Domain, Class 5, Transcription Factor 1
- preferred_term: SOX2
term:
id: NCIT:C61139
label: Transcription Factor SOX-2
- preferred_term: NANOG
term:
id: NCIT:C61135
label: Homeobox Protein NANOG
genes:
- preferred_term: POU5F1
term:
id: hgnc:9221
label: POU5F1
- preferred_term: SOX2
term:
id: hgnc:11195
label: SOX2
- preferred_term: NANOG
term:
id: hgnc:20857
label: NANOG
- preferred_term: LIN28A
term:
id: hgnc:15986
label: LIN28A
evidence:
- reference: PMID:36835562
reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
embryonal carcinoma (EC) has four upregulated genes, OCT4/POU5F1, SOX2, LIN28, and
NANOG. The EC panel can reprogram cells into iPSC, and both iPSC and EC can
differentiate into teratoma
explanation: >-
Names the four-factor pluripotency programme of embryonal carcinoma and its
reprogramming and differentiation capacity.
- reference: PMID:19369635
reference_title: "Differential expression of SOX2 and SOX17 in testicular germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All but one of the embryonal carcinomas showed diffuse SOX2 nuclear expression with
the one showing a focal reaction, whereas all were negative for SOX17.
explanation: >-
Documents the SOX2-positive, SOX17-negative pattern that defines the EC
pluripotency state and separates it from seminoma.
- reference: PMID:38922953
reference_title: "Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
different pluripotency associated factors (e.g. OCT3/4, SOX2, SOX17) play a crucial
role in GCT development and can be used as immunohistochemical markers allowing to
distinguish the different subtypes from each other in morphologically challenging
tissue specimens
explanation: >-
Supports the mechanistic and diagnostic centrality of the pluripotency factors in
germ cell tumour subtyping.
downstream:
- target: Unrestrained Primitive Epithelial Proliferation
description: >-
The stem-cell programme sustains a self-renewing, highly proliferative primitive
epithelial population.
- target: Multilineage Differentiation Into Other Germ Cell Tumour Histologies
description: >-
Retained pluripotency is what allows EC to generate teratomatous and extraembryonic
lineages within a mixed tumour.
- target: Intact Apoptotic Apparatus with Limited DNA Repair Capacity
description: >-
The embryonic-stem-cell-like state carries a low apoptotic threshold, in which p53
levels move inversely to OCT4/SOX2/NANOG on genotoxic stress.
- name: Unrestrained Primitive Epithelial Proliferation
description: >-
Embryonal carcinoma grows as sheets, glands and pseudopapillae of large, primitive,
epithelial-appearing cells with amphophilic cytoplasm, indistinct borders,
overlapping vesicular nuclei with prominent nucleoli, and a very high mitotic rate.
Areas of geographic (coagulative) necrosis reflect the mismatch between growth rate
and blood supply.
biological_scale: CELLULAR
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
- preferred_term: mitotic cell cycle
modifier: INCREASED
term:
id: GO:0000278
label: mitotic cell cycle
evidence:
- reference: PMID:19396148
reference_title: "Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
nuclear details are the most important morphological criterion for the diagnosis of
embryonal carcinoma in difficult-to-classify areas
explanation: >-
Confirms that the high-grade primitive nuclear morphology of this node is the
decisive diagnostic feature of embryonal carcinoma.
downstream:
- target: Lymphovascular Invasion and Early Metastatic Dissemination
description: >-
The rapidly proliferating primitive epithelial population invades lymphatics and
vessels early in its course.
- name: Multilineage Differentiation Into Other Germ Cell Tumour Histologies
description: >-
Because EC retains pluripotency it can differentiate along somatic (teratoma) and
extraembryonic (yolk sac tumour, choriocarcinoma) lineages. This is the mechanistic
reason EC is the most common component of post-pubertal mixed germ cell tumours and
only rarely occurs in pure form, and why a mixed tumour's serum marker profile (AFP
from yolk sac elements, beta-hCG from trophoblastic elements) often reflects
differentiated progeny rather than the EC component itself.
biological_scale: CELLULAR
biological_processes:
- preferred_term: cell differentiation
modifier: ABNORMAL
term:
id: GO:0030154
label: cell differentiation
evidence:
- reference: PMID:36835562
reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The EC panel can reprogram cells into iPSC, and both iPSC and EC can differentiate
into teratoma
explanation: >-
Directly supports embryonal carcinoma's capacity to differentiate into another germ
cell tumour histology.
- name: Lymphovascular Invasion and Early Metastatic Dissemination
description: >-
Embryonal carcinoma is the most aggressive of the ordinary non-seminomatous
histologies with respect to early spread. In clinical stage I non-seminoma, either
lymphovascular invasion or a high proportion of embryonal carcinoma in the
orchiectomy specimen identifies patients who harbour occult retroperitoneal or
haematogenous metastases despite negative staging, and these two features are the
basis of risk-adapted management (surveillance versus retroperitoneal lymph node
dissection versus adjuvant chemotherapy).
biological_scale: TISSUE
evidence:
- reference: PMID:24679874
reference_title: "Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Occult metastases were noted in 50% of patients with features such as
lymphovascular invasion or embryonal carcinoma predominance in the orchiectomy.
explanation: >-
Directly links embryonal carcinoma predominance to occult metastatic disease in
clinical stage I non-seminoma.
- reference: PMID:24679874
reference_title: "Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Seven patients (58.3%) with high risk features had occult metastatic disease vs
none (0%) without high risk features (log rank p = 0.031).
explanation: >-
Quantifies the discriminating power of the high-risk features (40% or greater
embryonal carcinoma, or lymphovascular invasion) in a paediatric and adolescent
cohort.
- name: Intact Apoptotic Apparatus with Limited DNA Repair Capacity
description: >-
Unlike most solid tumours, embryonal carcinoma and its sibling germ cell tumour
histologies retain wild-type TP53 and an unusually low apoptotic threshold, while
having limited capacity to repair platinum-induced DNA adducts. Cisplatin therefore
produces persistent DNA damage in a cell that is primed to die, and both the death
receptor (FAS/FASL) and the mitochondrial (Bax/Noxa versus Bcl-2) apoptotic pathways
are strongly engaged. Experimentally, p53 levels move inversely to OCT4, SOX2 and
NANOG on cisplatin exposure, tying the chemosensitivity directly to the pluripotency
state rather than to a separate lesion.
biological_scale: MOLECULAR
biological_processes:
- preferred_term: DNA repair
modifier: DECREASED
term:
id: GO:0006281
label: DNA repair
- preferred_term: extrinsic apoptotic signaling pathway
modifier: INCREASED
term:
id: GO:0097191
label: extrinsic apoptotic signaling pathway
- preferred_term: intrinsic apoptotic signaling pathway in response to DNA damage
modifier: INCREASED
term:
id: GO:0008630
label: intrinsic apoptotic signaling pathway in response to DNA damage
genes:
- preferred_term: TP53
term:
id: hgnc:11998
label: TP53
evidence:
- reference: PMID:37891379
reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients
using cisplatin-based combination therapy. Published data suggest that TGCTs are
sensitive to cisplatin due to limited DNA repair and presumably also to a
propensity to undergo apoptosis
explanation: >-
Supports the dual basis of this node - limited DNA repair plus a propensity to
undergo apoptosis.
- reference: PMID:37891379
reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
both the death receptor and the mitochondrial apoptotic pathway become strongly
activated in TTC following cisplatin treatment, explaining, together with
attenuated DNA repair, their unique sensitivity toward platinum-based anticancer
drugs
explanation: >-
Identifies the two apoptotic routes engaged, which is the specific mechanism
asserted here.
- reference: PMID:23625774
reference_title: "MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
p53 levels were inversely associated with the expression of Oct4, Sox2, and Nanog
in response to cisplatin.
explanation: >-
Links the p53 response of embryonal carcinoma cells to their pluripotency factor
levels, connecting this node to the upstream pluripotency programme.
downstream:
- target: Exceptional Cisplatin Chemosensitivity
description: >-
Persistent unrepaired platinum damage in an apoptosis-primed cell produces massive
tumour cell death.
- name: Exceptional Cisplatin Chemosensitivity
description: >-
The practical consequence of the preceding node: even metastatic germ cell tumours,
including embryonal carcinoma, are cured in the great majority of patients with
cisplatin-based combination chemotherapy. This is the mechanistic inverse of the
apoptosis evasion that characterises most solid tumours, and it is the reason
chemotherapy - rather than a targeted agent - remains the backbone of treatment
despite the near-universal 12p and KRAS dosage lesion.
biological_scale: ORGANISM
biological_processes:
- preferred_term: cellular response to cisplatin
term:
id: GO:0072719
label: cellular response to cisplatin
- preferred_term: apoptotic process
modifier: INCREASED
term:
id: GO:0006915
label: apoptotic process
evidence:
- reference: PMID:37175579
reference_title: "Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Testicular germ-cell tumors (TGCT) have been widely recognized for their
outstanding survival rates, commonly attributed to their high sensitivity to
cisplatin-based therapies
explanation: >-
Confirms the clinical outcome that this node asserts follows from the intact
apoptotic apparatus.
downstream:
- target: Acquired Cisplatin Resistance
description: >-
A minority of tumours escape this sensitivity through TP53 pathway inactivation or
somatic-type transformation.
- name: Acquired Cisplatin Resistance
description: >-
The escape branch. A minority of germ cell tumours become platinum-refractory, and
the alterations associated with that transition are the ones that break the intact
p53/apoptosis axis: TP53 mutation, MDM2 amplification, and epigenetic reprogramming,
frequently in the setting of somatic-type malignant transformation. TP53 mutation is
markedly enriched in mediastinal (extragonadal) tumours, matching their worse
prognosis.
biological_scale: MOLECULAR
genes:
- preferred_term: TP53
term:
id: hgnc:11998
label: TP53
biological_processes:
- preferred_term: intrinsic apoptotic signaling pathway in response to DNA damage
modifier: DECREASED
term:
id: GO:0008630
label: intrinsic apoptotic signaling pathway in response to DNA damage
evidence:
- reference: PMID:41384700
reference_title: "Molecular pathology of testicular germ cell tumours: an update for practicing pathologists."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Alterations associated with the formation of a somatic-type malignancy and/or the
development of cisplatin resistance include TP53 mutations or MDM2 gene
amplifications as well as epigenetic alterations.
explanation: >-
Names the specific alterations that underlie loss of the platinum sensitivity
modelled upstream.
- reference: PMID:36030288
reference_title: "Molecular correlates of male germ cell tumors with overgrowth of components resembling somatic malignancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS and TP53 mutations were identified by DNA sequencing in 28% of cases each,
with enrichment of TP53 mutations in mediastinal tumors (86%).
explanation: >-
Quantifies TP53 mutation in germ cell tumours with somatic-type malignancy and its
mediastinal enrichment.
histopathology:
- name: Glandular and Solid Growth Pattern
finding_term:
preferred_term: Glandular Pattern
term:
id: NCIT:C35929
label: Glandular Pattern
description: >-
Embryonal carcinoma grows in solid sheets and in glandular (pseudoglandular)
formations of primitive epithelial-appearing cells.
- name: Pseudopapillary Architecture
finding_term:
preferred_term: Pseudopapillary Pattern
term:
id: NCIT:C35912
label: Pseudopapillary Pattern
description: >-
Pseudopapillary structures, formed where tumour cells drape over stromal cores or
around necrotic centres, are part of the architectural repertoire named in the NCI
Thesaurus definition of embryonal carcinoma that MONDO adopts.
- name: Geographic Coagulative Necrosis
finding_term:
preferred_term: Coagulative Necrosis
term:
id: NCIT:C39608
label: Coagulative Necrosis
description: >-
Broad confluent zones of coagulative (geographic) necrosis are characteristic and
reflect the tumour outgrowing its blood supply.
- name: High Mitotic Rate
finding_term:
preferred_term: Increased Mitotic Activity
term:
id: NCIT:C163732
label: Increased Mitotic Activity
description: >-
Brisk mitotic activity, including atypical mitoses, is a constant feature and part of
the high-grade nuclear picture that defines the diagnosis.
- name: OCT3/4-Positive, SOX2-Positive, CD30-Positive Immunophenotype
diagnostic: true
frequency: VERY_FREQUENT
description: >-
The diagnostic immunoprofile. OCT3/4 is shared with seminoma/germinoma and GCNIS;
SOX2 and CD30 are what mark the tumour as embryonal carcinoma rather than seminoma,
and SOX17 is negative in EC while positive in seminoma. Cytokeratin and EMA are also
positive, unlike in seminoma.
evidence:
- reference: PMID:19396148
reference_title: "Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SOX2 is expressed in embryonal carcinoma and primitive neuroectoderm of teratoma,
and unlike OCT3/4, not in intra-tubular germ cell neoplasia and seminoma
explanation: >-
Establishes SOX2 as the discriminating marker between embryonal carcinoma and
seminoma/GCNIS.
- reference: PMID:26191277
reference_title: "Extragonadal malignant germ cell tumors: a clinicopathological and immunohistochemical analysis of 48 cases at a single Chinese institution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
CD30, EMA and CK AE1/3 staining were positive in embryonal carcinoma.
explanation: >-
Documents the CD30, EMA and cytokeratin positivity of embryonal carcinoma in an
extragonadal series.
- reference: PMID:32205480
reference_title: "Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the most commonly used immunomarker panel includes OCT3/4, placental alkaline
phosphate, D2-40, SALL4, CD117, and CD30 for GCTs and the documentation of germ
cell neoplasia in situ (GCNIS)
explanation: >-
Consensus statement placing OCT3/4 and CD30 in the routine germ cell tumour
immunopanel.
phenotypes:
- category: Neoplastic
name: Testicular Mass
description: >-
A painless or mildly tender testicular mass is the usual presentation of testicular
embryonal carcinoma, most often within a mixed non-seminomatous germ cell tumour.
phenotype_term:
preferred_term: Testicular neoplasm
term:
id: HP:0010788
label: Testicular neoplasm
subtype: Testicular EC
evidence:
- reference: PMID:38922953
reference_title: "Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Type II GCT include seminoma, embryonal carcinoma, choriocarcinoma,
postpubertal-type teratoma and postpubertal-type YST.
explanation: >-
Supports embryonal carcinoma as a testicular germ cell tumour histology presenting
as a testicular neoplasm.
- category: Neoplastic
name: Ovarian Mass
description: >-
Ovarian embryonal carcinoma presents as a large, unilateral, predominantly solid
adnexal mass with inhomogeneous echogenicity and abundant vascularity on ultrasound,
typically in a girl or young woman.
phenotype_term:
preferred_term: Ovarian neoplasm
term:
id: HP:0100615
label: Ovarian neoplasm
subtype: Ovarian EC
evidence:
- reference: PMID:33142349
reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A unilateral, large solid tumor with inhomogeneous echogenicity of the solid tissue
and with dispersed small cystic areas in a young woman should raise the suspicion
of a rare malignant germ cell tumor.
explanation: >-
Describes the presenting adnexal mass phenotype for the rare malignant ovarian germ
cell tumours studied, which included embryonal carcinoma.
- category: Neoplastic
name: Intracranial Tumour
description: >-
Intracranial embryonal carcinoma presents as a pineal or suprasellar mass, sometimes
bifocal, in a child or adolescent.
phenotype_term:
preferred_term: Brain neoplasm
term:
id: HP:0030692
label: Brain neoplasm
subtype: CNS EC
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These tumors commonly arise in the pineal and suprasellar regions, with a subset
presenting as bifocal lesions.
explanation: >-
Establishes the intracranial locations at which the NGGCT group, including
embryonal carcinoma, presents.
- category: Clinical
name: Raised Intracranial Pressure
description: >-
Headache, visual disturbance and signs of raised intracranial pressure are the
characteristic presenting features of central nervous system germ cell tumours,
reflecting obstruction of CSF pathways at the pineal region.
phenotype_term:
preferred_term: Increased intracranial pressure
term:
id: HP:0002516
label: Increased intracranial pressure
subtype: CNS EC
evidence:
- reference: PMID:26191277
reference_title: "Extragonadal malignant germ cell tumors: a clinicopathological and immunohistochemical analysis of 48 cases at a single Chinese institution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Headache, visual disturbances, endocrine abnormalities, and signs of increased
intracranial pressure were common clinical symptoms in CNS MGCTs.
explanation: >-
Documents raised intracranial pressure as a common presentation of CNS malignant
germ cell tumours.
- category: Clinical
name: Abdominal or Retroperitoneal Mass
description: >-
Retroperitoneal nodal metastasis, or a primary retroperitoneal extragonadal tumour,
presents as an abdominal mass with or without back pain.
phenotype_term:
preferred_term: Abdominal mass
term:
id: HP:0031500
label: Abdominal mass
evidence:
- reference: PMID:26191277
reference_title: "Extragonadal malignant germ cell tumors: a clinicopathological and immunohistochemical analysis of 48 cases at a single Chinese institution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Abdominal mass with or without pain, backache and weight loss were common clinical
presentations in retroperitoneal MGCTs.
explanation: >-
Supports the abdominal-mass presentation of retroperitoneal malignant germ cell
tumours.
- category: Biochemical
name: Elevated Serum Alpha-Fetoprotein
description: >-
AFP elevation in a tumour containing embryonal carcinoma generally signals a yolk sac
tumour component; pure embryonal carcinoma is not itself an AFP producer, but any AFP
elevation mandates non-seminomatous management. AFP is central to the marker-based
diagnosis of intracranial NGGCT, where biopsy may be avoided.
phenotype_term:
preferred_term: Elevated circulating alpha-fetoprotein concentration
term:
id: HP:0006254
label: Elevated circulating alpha-fetoprotein concentration
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
NGGCTs include embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratomas
and often secrete tumor markers like alpha-fetoprotein (AFP) and beta-hCG, which
guide diagnosis and treatment without biopsy.
explanation: >-
Supports AFP as a diagnostic marker of the NGGCT group that contains embryonal
carcinoma.
- category: Biochemical
name: Elevated Serum Beta-hCG
description: >-
Beta-hCG elevation reflects syncytiotrophoblastic or choriocarcinomatous elements
within a germ cell tumour and, like AFP, is used to diagnose and monitor
non-seminomatous disease including intracranial NGGCT.
phenotype_term:
preferred_term: Elevated circulating beta chorionic gonadotropin concentration
term:
id: HP:6000485
label: Elevated circulating beta chorionic gonadotropin concentration
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
often secrete tumor markers like alpha-fetoprotein (AFP) and beta-hCG, which guide
diagnosis and treatment without biopsy
explanation: >-
Supports beta-hCG as a diagnostic marker of the NGGCT group that contains embryonal
carcinoma.
biochemical:
- name: OCT3/4 Nuclear Expression
biomarker_term:
preferred_term: POU Domain, Class 5, Transcription Factor 1
term:
id: NCIT:C61142
label: POU Domain, Class 5, Transcription Factor 1
notes: >-
Diffuse strong nuclear OCT3/4 is present in essentially all embryonal carcinomas, and
also in seminoma and GCNIS - it establishes germ cell origin but does not by itself
separate EC from seminoma.
evidence:
- reference: PMID:19396148
reference_title: "Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the staining patterns were OCT3/4 -3+, all seminomas, embryonal carcinomas and
intra-tubular germ cell neoplasia
explanation: >-
Documents uniformly strong OCT3/4 staining in embryonal carcinoma alongside
seminoma and GCNIS.
- name: SOX2 Nuclear Expression
biomarker_term:
preferred_term: Transcription Factor SOX-2
term:
id: NCIT:C61139
label: Transcription Factor SOX-2
specificity: >-
Positive in embryonal carcinoma and in primitive neuroectoderm of immature teratoma;
negative in seminoma, GCNIS and yolk sac tumour.
evidence:
- reference: PMID:19369635
reference_title: "Differential expression of SOX2 and SOX17 in testicular germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SOX2 and SOX17 expression patterns can distinguish between seminoma and embryonal
carcinoma, and this distinction may be diagnostically useful.
explanation: >-
Supports SOX2 as the discriminating biomarker between seminoma and embryonal
carcinoma.
- name: CD30 Membranous Expression
biomarker_term:
preferred_term: Tumor Necrosis Factor Receptor Superfamily Member 8
term:
id: NCIT:C38906
label: Tumor Necrosis Factor Receptor Superfamily Member 8
specificity: >-
Among germ cell tumour histologies CD30 is essentially restricted to embryonal
carcinoma, which makes it the workhorse marker for identifying EC components. CD30
expression can be lost after chemotherapy.
evidence:
- reference: PMID:26191277
reference_title: "Extragonadal malignant germ cell tumors: a clinicopathological and immunohistochemical analysis of 48 cases at a single Chinese institution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
CD30, EMA and CK AE1/3 staining were positive in embryonal carcinoma.
explanation: >-
Documents CD30 positivity as an embryonal carcinoma marker in extragonadal germ
cell tumours.
- name: NANOG Expression
biomarker_term:
preferred_term: Homeobox Protein NANOG
term:
id: NCIT:C61135
label: Homeobox Protein NANOG
notes: >-
NANOG is one of the four upregulated pluripotency genes of the embryonal carcinoma
panel and is resident on 12p, the chromosome arm gained in essentially all
GCNIS-derived germ cell tumours.
evidence:
- reference: PMID:36835562
reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
embryonal carcinoma (EC) has four upregulated genes, OCT4/POU5F1, SOX2, LIN28, and
NANOG
explanation: >-
Names NANOG among the upregulated genes of the embryonal carcinoma panel.
genetic:
- name: 12p gain (isochromosome 12p)
relationship_type: SOMATIC_DRIVER
variant_origin: SOMATIC
notes: >-
Not a gene-level association: the lesion is arm-level gain of 12p, most often as an
isochromosome. It is recorded here because it is the defining somatic alteration of
embryonal carcinoma and is used diagnostically. The 12p genes implicated in its
effect (NANOG, KRAS, CCND2, LDHB) are attached to the corresponding pathophysiology
node.
evidence:
- reference: PMID:36030288
reference_title: "Molecular correlates of male germ cell tumors with overgrowth of components resembling somatic malignancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Gains in the short arm of chromosome 12 were seen in 91% of cases, likely
reflecting the presence of isochromosome 12p.
explanation: >-
Quantifies 12p gain in a molecularly profiled male germ cell tumour cohort.
- name: TP53
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
relationship_type: MODIFIER
variant_origin: SOMATIC
notes: >-
TP53 is characteristically wild-type in germ cell tumours, and that is the basis of
their platinum sensitivity. Somatic TP53 mutation is therefore recorded as a
resistance modifier rather than a driver, and it is strongly enriched in mediastinal
(extragonadal) disease.
evidence:
- reference: PMID:36030288
reference_title: "Molecular correlates of male germ cell tumors with overgrowth of components resembling somatic malignancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KRAS and TP53 mutations were identified by DNA sequencing in 28% of cases each,
with enrichment of TP53 mutations in mediastinal tumors (86%).
explanation: >-
Documents somatic TP53 mutation frequency and its mediastinal enrichment in germ
cell tumours with somatic-type malignancy.
treatments:
- name: Radical Inguinal Orchiectomy
description: >-
Removal of the affected testis and spermatic cord through an inguinal incision is
both the diagnostic and the initial therapeutic procedure for testicular embryonal
carcinoma, and it supplies the orchiectomy specimen on which the risk-defining
features (percentage embryonal carcinoma, lymphovascular invasion) are assessed.
therapeutic_modality: SURGERY
treatment_term:
preferred_term: orchiectomy
term:
id: NCIT:C15288
label: Orchiectomy
target_mechanisms:
- target: Unrestrained Primitive Epithelial Proliferation
treatment_effect: INHIBITS
description: >-
Excision physically removes the proliferating primitive epithelial population at
the primary site.
evidence:
- reference: PMID:24679874
reference_title: "Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We tested the hypothesis that lymphovascular invasion, or 40% or greater embryonal
carcinoma in the orchiectomy specimen, would increase the risk of occult metastases
explanation: >-
Confirms orchiectomy as the procedure that both treats the primary and provides the
specimen used for risk stratification.
- name: Cisplatin-Based Combination Chemotherapy (BEP)
description: >-
Bleomycin, etoposide and cisplatin is the standard regimen for metastatic and
high-risk non-seminomatous germ cell tumours including embryonal carcinoma. Its
efficacy rests on the tumour's retained wild-type TP53, low apoptotic threshold and
limited DNA repair capacity, which together convert platinum adducts into
overwhelming apoptosis; cure rates exceed 80% even with metastatic disease.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: chemotherapy
term:
id: NCIT:C15632
label: Chemotherapy
therapeutic_agent:
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- preferred_term: etoposide
term:
id: CHEBI:4911
label: etoposide
regimen_term:
preferred_term: BEP regimen
term:
id: NCIT:C63488
label: BEP Regimen
target_mechanisms:
- target: Intact Apoptotic Apparatus with Limited DNA Repair Capacity
treatment_effect: ACTIVATES
description: >-
Cisplatin does not correct a lesion here; it exploits the tumour's intact apoptotic
apparatus, driving both the death-receptor and mitochondrial pathways.
evidence:
- reference: PMID:37891379
reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients
using cisplatin-based combination therapy
explanation: >-
Quantifies the cure rate achieved by cisplatin-based combination therapy in
metastatic germ cell tumours.
- name: Retroperitoneal Lymph Node Dissection
description: >-
Primary or post-chemotherapy retroperitoneal lymph node dissection removes the
principal landing zone for testicular germ cell tumour metastases. It is used in
clinical stage I non-seminoma with high-risk pathology - embryonal carcinoma
predominance or lymphovascular invasion - where roughly half of patients harbour
occult nodal disease.
therapeutic_modality: SURGERY
treatment_term:
preferred_term: retroperitoneal lymph node dissection
term:
id: NCIT:C48184
label: Retroperitoneal Lymph Node Dissection
target_mechanisms:
- target: Lymphovascular Invasion and Early Metastatic Dissemination
treatment_effect: INHIBITS
description: >-
Removes occult nodal deposits in the retroperitoneal landing zone before they
progress.
evidence:
- reference: PMID:24679874
reference_title: "Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Of these patients 14 (60.9%) were on surveillance, 9 (39.1%) underwent primary
retroperitoneal lymph node dissection and none received initial chemotherapy.
explanation: >-
Documents primary retroperitoneal lymph node dissection as one of the management
options in clinical stage I non-seminoma.
- name: Radiotherapy for Intracranial NGGCT
description: >-
Intracranial non-germinomatous germ cell tumours, including embryonal carcinoma,
require high-dose radiotherapy after induction chemotherapy, together with resection
of residual tumour. Field selection matters: focal radiotherapy alone has been
associated with metastatic (ventricular and spinal) failure, so craniospinal or
whole-ventricular fields are generally preferred.
therapeutic_modality: RADIOTHERAPY
treatment_term:
preferred_term: radiation therapy
term:
id: NCIT:C15313
label: Radiation Therapy
context: CNS EC
evidence:
- reference: PMID:42115464
reference_title: "Germinomas and Non-germinomatous Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
NGGCTs require intensive chemotherapy, surgical resection of residual tumor, and
high-dose radiotherapy.
explanation: >-
Establishes high-dose radiotherapy as part of standard intracranial NGGCT
management.
- reference: PMID:29380526
reference_title: "Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This pattern of failure data adds to growing evidence suggesting chemotherapy
followed by focal radiotherapy alone is inadequate in controlling localized NGGCT.
explanation: >-
Supports the field-selection caveat that focal radiotherapy alone is insufficient
for intracranial NGGCT.
diagnosis:
- name: Immunohistochemical Distinction of Embryonal Carcinoma from Seminoma
description: >-
The core diagnostic problem for embryonal carcinoma is separating it from
seminoma/germinoma, because that distinction changes management. Morphology
(high-grade overlapping nuclei, glandular and pseudopapillary architecture) is
supported by immunohistochemistry: both are OCT3/4-positive, but embryonal carcinoma
is SOX2-positive, CD30-positive, cytokeratin-positive and SOX17-negative, whereas
seminoma is the reverse.
evidence:
- reference: PMID:32205480
reference_title: "Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Immunohistochemical staining is optional in the following scenarios: identification
of GCNIS, distinguishing embryonal carcinoma from seminoma, confirming presence of
yolk sac tumor and/or choriocarcinoma
explanation: >-
ISUP consensus naming the embryonal-carcinoma-versus-seminoma distinction as a
recognised indication for immunohistochemistry.
differential_diagnoses:
- name: Seminoma / germinoma
description: >-
Shares OCT3/4 positivity and germ cell origin. Distinguished by SOX17 positivity,
SOX2 negativity and CD30 negativity, plus lower-grade nuclei and a lymphocytic
infiltrate.
- name: Yolk sac tumour
description: >-
Also a non-seminomatous histology, but AFP-producing, GDF3-positive and negative for
CD30.
- name: Somatic carcinoma metastatic to the gonad or midline
description: >-
Cytokeratin positivity can mislead. Detection of 12p gain establishes germ cell
origin and is the recommended tie-breaker in primary and metastatic lesions.
discussions:
- discussion_id: ec_chemosensitivity_no_matching_module
kind: INTERPRETATION
status: OPEN
prompt: >-
Should the intact-apoptotic-machinery route to exceptional platinum chemosensitivity
seen in embryonal carcinoma be factored out into a reusable mechanism module, and if
so, is it a module in its own right or the negative pole of the existing
resisting_cell_death module?
attaches_to:
- pathophysiology#Intact Apoptotic Apparatus with Limited DNA Repair Capacity
- pathophysiology#Exceptional Cisplatin Chemosensitivity
rationale: >-
This entry deliberately declares no conforms_to links. The candidate hallmark modules
do not honestly fit. resisting_cell_death models a BCL-2-family rheostat shifted
toward survival; embryonal carcinoma is its mechanistic inverse - wild-type TP53, a
low apoptotic threshold, and strong Bax/Noxa-driven death - so conformance would
assert the opposite of the curated biology. genome_instability_mutation requires a
genome-maintenance defect producing a mutator phenotype; germ cell tumours have
arm-level aneuploidy (12p gain) on a strikingly quiet point-mutation background and a
DNA-damage response that kills rather than mutates, so that module's central claim
does not hold either. sustaining_proliferative_signaling was also considered and
rejected: KRAS is gained by dosage on 12p, but activating KRAS and KIT mutations are
concentrated in seminoma and targetable lesions are rare, so a constitutive mitogenic
pathway activation node is not evidenced here. A dedicated module (provisional shape:
therapy-exploitable apoptotic priming) would be a better home for this chain and
would immediately gain the sibling germ cell tumour entries as conformers.
notes: >-
Raised while curating this entry against issue 8738, whose triage comment made the
same observation independently.
notes: >-
Scope. This entry models embryonal carcinoma as an entity, across the four MONDO
subclasses. The site-specific disease entries remain separate and are not superseded:
Testicular_Germ_Cell_Tumor, Mixed_Germ_Cell_Tumor,
Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary and
Central_Nervous_System_Germ_Cell_Tumor each retain an embryonal carcinoma component
block, now bound where possible to the appropriate MONDO term.
Pure versus component. Embryonal carcinoma is far more often a component of a mixed
germ cell tumour than a pure tumour. The issue that requested this entry suggested a
component-of-mixed-germ-cell-tumour subtype; that was not created, because it has no
MONDO identifier and cross-cuts the four site subclasses rather than sitting alongside
them. The component role is captured in the pathophysiology (multilineage
differentiation) and in the Mixed_Germ_Cell_Tumor entry instead.
Serum markers. Neither AFP nor beta-hCG is produced by embryonal carcinoma itself; the
phenotype entries record them because they are how an NGGCT containing an EC component
is diagnosed and monitored, and the descriptions say so explicitly rather than implying
EC secretes them.
references:
- reference: PMID:32205480
title: "Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors."
- reference: PMID:41384700
title: "Molecular pathology of testicular germ cell tumours: an update for practicing pathologists."
- reference: PMID:38922953
title: "Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics."